Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It plans to enroll 374 participants.
Also called NCT02790632
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 374 participants
- Sponsor
- Edge Therapeutics Inc
- Registry
-
NCT02790632
-
- Other papers using this trial's data
- Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Austria, Canada, Czechia, Finland, Germany, Hong Kong SAR China, Israel, New Zealand, Singapore
- Registry status
- Terminated
Technical summary
Registry record NCT02790632. Randomized; quadruple masking; primary purpose treatment. Start 2016-07 (registry gives no type); primary completion 2018-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage
- Acronym
- NEWTON2
- Condition
- Subarachnoid Hemorrhage, Aneurysmal
- Intervention (Drug)
- EG-1962 (nimodipine microparticles)
- Intervention (Drug)
- Enteral Nimodipine
- Lead sponsor
- Edge Therapeutics Inc
Record details
- Record id
cardio:ct-nct02790632- Content hash
68e318249bfeb89f77e6192a08fa89cb633ef661cb1e7b556479e760270fb271